Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.

about

Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.

Item

http://www.wikidata.org/entity/Q35777143

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Second-Line Treatment of Her2- ...... Population Based Cohort Study.

@ast

Second-Line Treatment of Her2- ...... Population Based Cohort Study.

@en

type

Item

label

Second-Line Treatment of Her2- ...... Population Based Cohort Study.

@ast

Second-Line Treatment of Her2- ...... Population Based Cohort Study.

@en

prefLabel

Second-Line Treatment of Her2- ...... Population Based Cohort Study.

@ast

Second-Line Treatment of Her2- ...... Population Based Cohort Study.

@en

P1476

Second-Line Treatment of Her2- ...... Population Based Cohort Study.

@en

P2093

Ariel Hammerman

http://www.w3.org/2001/XMLSchema#string

Haim Bitterman

http://www.w3.org/2001/XMLSchema#string

Ilan Feldhamer

http://www.w3.org/2001/XMLSchema#string

Rinat Yerushalmi

http://www.w3.org/2001/XMLSchema#string

P2860

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Development of a comorbidity index using physician claims data.

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial

Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.

FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

P304

e0138229

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0138229

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sari Greenberg-Dotan

P577

2015-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282041563

http://www.w3.org/2001/XMLSchema#string

P698

26375590

http://www.w3.org/2001/XMLSchema#string

P932

4574060

http://www.w3.org/2001/XMLSchema#string